Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$53.1M
Filings
106
Firms Hired
1
Active Period
1999–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Diagnostics Testing Preparedness Plan Act of 2025
2026 · third_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Client expense: $90,000 · Firm income: —
Matched citations: H.R.1108
Diagnostics Testing Preparedness Plan Act of 2025
2026 · third_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness
Client expense: $90,000 · Firm income: —
Matched citations: H.R.1108
RESULTS Act
2026 · third_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Client expense: $90,000 · Firm income: —
Matched citations: H.R. 5269
RESULTS Act
2026 · third_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.
Client expense: $90,000 · Firm income: —
Matched citations: H.R. 5269
Department of State Policy Provisions Act
2026 · third_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
(FOR) HIV Testing in the President's Emergency Plan for AIDS Relief, including funding to support PEPFAR laboratory services and testing in FY2027 Appropriations for National Security, Department of State, and Related Programs, and PEPFAR Reauthorization in the FY2026 State Department Reauthorization (H.R.5300 - Department of State Policy Provisions Act)
Client expense: $90,000 · Firm income: —
Matched citations: H.R.5300
Ensuring Patient Access to Critical Breakthrough Products Act
2026 · third_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.
Client expense: $90,000 · Firm income: —
Matched citations: H.R.5343
Ensuring Patient Access to Critical Breakthrough Products Act
2026 · third_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Client expense: $90,000 · Firm income: —
Matched citations: H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
2026 · third_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.
Client expense: $90,000 · Firm income: —
Matched citations: S.1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
2026 · third_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Client expense: $90,000 · Firm income: —
Matched citations: S.1717
RESULTS Act
2026 · third_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.
Client expense: $90,000 · Firm income: —
Matched citations: S. 2761
RESULTS Act
2026 · third_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Client expense: $90,000 · Firm income: —
Matched citations: S. 2761
Diagnostics Testing Preparedness Plan Act of 2025
2026 · second_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Client expense: $90,000 · Firm income: —
Matched citations: H.R.1108
Diagnostics Testing Preparedness Plan Act of 2025
2026 · second_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness
Client expense: $90,000 · Firm income: —
Matched citations: H.R.1108
RESULTS Act
2026 · second_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Client expense: $90,000 · Firm income: —
Matched citations: H.R. 5269
RESULTS Act
2026 · second_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Client expense: $90,000 · Firm income: —
Matched citations: H.R. 5269
Department of State Policy Provisions Act
2026 · second_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
(FOR) HIV Testing in the President's Emergency Plan for AIDS Relief, including funding to support PEPFAR laboratory services and testing in FY2027 Appropriations for National Security, Department of State, and Related Programs, and PEPFAR Reauthorization in the FY2026 State Department Reauthorization (H.R.5300 - Department of State Policy Provisions Act)
Client expense: $90,000 · Firm income: —
Matched citations: H.R.5300
Ensuring Patient Access to Critical Breakthrough Products Act
2026 · second_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Client expense: $90,000 · Firm income: —
Matched citations: H.R.5343
Ensuring Patient Access to Critical Breakthrough Products Act
2026 · second_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Client expense: $90,000 · Firm income: —
Matched citations: H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
2026 · second_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Client expense: $90,000 · Firm income: —
Matched citations: S.1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
2026 · second_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Client expense: $90,000 · Firm income: —
Matched citations: S.1717
RESULTS Act
2026 · second_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Client expense: $90,000 · Firm income: —
Matched citations: S. 2761
RESULTS Act
2026 · second_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Client expense: $90,000 · Firm income: —
Matched citations: S. 2761
Diagnostics Testing Preparedness Plan Act of 2025
2026 · first_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Client expense: $160,000 · Firm income: —
Matched citations: H.R.1108
Diagnostics Testing Preparedness Plan Act of 2025
2026 · first_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Client expense: $160,000 · Firm income: —
Matched citations: H.R.1108
RESULTS Act
2026 · first_quarter · Firm: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Client expense: $160,000 · Firm income: —
Matched citations: H.R. 5269
Source: Senate LDA